Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Psilocybin studies

Explore psilocybin studies by research question and study design. Compare human trials, observational reports, reviews and preprints with source-linked evidence.

Free access · No subscription for research tools or data exports

Understand the different kinds of psilocybin study

Psilocybin studies include randomized human trials, observational reports, studies in healthy volunteers, animal and laboratory experiments, and registered trial plans. They answer different questions. A registered study establishes a research plan; an observational improvement does not by itself establish causation. A positive randomized endpoint still needs interpretation alongside the comparator, follow-up and adverse events.

Human clinical studies

Compare the selected depression and alcohol-use studies by population, treatment setting, primary endpoint and follow-up. Their findings concern the supervised interventions studied, not unrestricted use.

Compare selected findings and limitations

Current and recruiting studies

Use exact registry recruitment status to locate ongoing psilocybin clinical studies. Start and completion dates are registry facts; they do not establish efficacy, publication or personal eligibility.

Recruiting psilocybin studies

Laboratory and mechanism studies

Mechanistic and animal experiments can help formulate hypotheses. Their endpoints and populations differ from clinical outcomes, so they should not be presented as direct evidence of treatment effectiveness.

Explore mechanism-related literature

See the MSCA psilocybin–telomere research story for a source-linked hypothesis and independent preclinical follow-up, with limitations. Available in 20 languages.

Reviews, protocols and preprints

Reviews synthesise existing work, protocols describe planned methods, and preprints have not been peer reviewed. Preserve these distinctions when building an evidence set.

Research reading checklist

Browse indexed psilocybin studies

4958 matching records; first 20 shown. Derived labels aid screening and need verification against the methods. Coverage is broad but not exhaustive.

Single-dose psilocybin superior to placebo for MDD in community setting · 2026-12-01 · The Brown University Psychopharmacology Update · PublishedPilot study supports broader research on psilocybin for anorexia nervosa · 2026-12-01 · The Brown University Psychopharmacology Update · PublishedSingle dose of psilocybin shows extended benefit in depression trial · 2026-12-01 · The Brown University Psychopharmacology Update · PublishedQuantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurementPérez Rosal Sergio R., Faber Sonya C. · 2026-12-01 · Psychedelics · PublishedMindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelAlbertyn Christopher P., Richard Jérémie, Shore Ron, Carlson Linda E. · 2026-12-01 · Psychedelics · PublishedModelling vortex interactions reveals distinct patterns of brain reconfiguration following psilocybin and escitalopramAcosta-Gordo, A.; Dagnino, P. C.; Sanz Perl, Y.; Carhart-Harris, R.; Erritzoe, D.; Nutt, D. J.; Kringelbach, M. L.; Deco, G. · 2026-11-19 · bioRxiv · PREPRINT (not peer reviewed)Psilocybin reproducibilityLewis Sian · 2026-11-19 · Nature Reviews Neuroscience · PublishedMescaline enhances emotional empathy via 5-HT receptor activation.Klaiber A, Vizeli P, Varghese N, Eckert A, Liechti ME, Schmid Y · 2026-11-19 · Journal of psychopharmacology (Oxford, England) · PublishedTargeting CGRP signaling reverses maladaptive neurogenic immunosuppression in head and neck squamous cell carcinoma models.Idlett-Ali SL, Nguyen AT, Abdelazeem KN, Nguyen D, Olimpo NA, Knitz M, Gadwa J, Weiskpof T, Hodgson C, Kumar H, Ceja Galindo D, Gray T, Puram SV, Miller DL, Nicol GE, Saviola AJ, Osborne DG, Karam SD · 2026-11-19 · The Journal of clinical investigation · PublishedTaxonomic diversity and psilocybin detection in “superfamily” Strophariacea from China, with descriptions of two new speciesCao Bin, Yang Wen-Qiang, Feng Hai-Ying, He Mao-Qiang, Li Jia-Xin, Zhao Rui-Lin, Phurbu Dorji · 2026-11-18 · IMA Fungus · PublishedNovel quantification method for psilocin in brain tissues using liquid chromatography-tandem mass spectrometry.Khajavinia A, Reekie J, Michel D, Laprairie RB, El-Aneed A. · 2026-11-18 · Analytical methods: advancing methods and applications · PublishedA Placebo Cannot Be Psychedelic: Why psychedelic trials need dose, not mimicry, as their controlLiedtke W. · 2026-11-18 · PsyArXiv · PREPRINT (not peer reviewed)Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseNational Institute on Aging (NIA) · 2026-11-18 · ClinicalTrials.gov · CLINICAL TRIALToward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted PsychotherapyKyle Greenway · 2026-11-18 · ClinicalTrials.gov · CLINICAL TRIALPsilocybin induces delayed and dynamic changes in human sleep neurophysiology: Results from a randomized controlled trial of psilocybin assisted therapy in patients with comorbid major depressive and alcohol use disorderReid MJ, Weissman E, Martinez LL, Zahid Z, DuPont CM, Dai H, Finan PH, Barrett FS. · 2026-11-17 · Research Square · PREPRINT (not peer reviewed)Psychedelic treatment for headache disorders.Zorrilla E, Schindler EAD. · 2026-11-17 · Nature reviews. Neurology · PublishedMultidimensional Self-Transcendent Experiences in Psychedelic Use: Distinct Associations with Mindset, Affect, and Positive EffectsChwyl C, Luoma JB. · 2026-11-17 · PsyArXiv · PREPRINT (not peer reviewed)An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeCharles Raison · 2026-11-17 · ClinicalTrials.gov · CLINICAL TRIALEfficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsCentre Hospitalier Universitaire de Nīmes · 2026-11-17 · ClinicalTrials.gov · CLINICAL TRIALA Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for DepressionWashington University School of Medicine · 2026-11-17 · ClinicalTrials.gov · CLINICAL TRIAL

Research questions with source-linked context

Publication dates, study dates and indexing dates may differ. Clinical trial registrations describe planned methods, while primary reports describe findings. Read the editorial policy for source tracking, corrections and classification limits.